Count GlaxoSmithKline's Puerto Rican plant as an early Avandia casualty. The drug maker will close the factory in Cidra, Puerto Rico, and transfer production of the diabetes med (and its cousin Avandamet) to other plants. The 900-strong workforce in Cidra will be cut to 250 by year's end.
Of course, the Puerto Rican shutdown is just part of the cost-cutting pain at Glaxo. Yesterday, the company announced a big restructuring plan that will trim $1.4 billion in costs over the next four years and shrink its payroll by at least 5,000. Glaxo also plans to outsource manufacturing of its off-patent drugs, so some 40 percent of the job cuts will come in that sphere. Implementing the restructuring plan is expected to cost $3.1 billion.
Glaxo to cut $1.4B on falling sales. Report
Top five layoffs of 2007. Special report
VA marks Avandia off formulary. Report
What to do with Avandia sales force? Report
Expert committee says Avandia should stay. Report
Docs shunning Avandia in wake of safety study. Report